Patients with major depressive disorder who meet criteria for borderline personality disorder frequently exhibit atypical features, including mood reactivity, and may be more likely to respond to MAOIs and SSRIs than to tricyclic antidepressants
Ref: - Parsons, B., Quitkin, F.M., McGrath, P.J., Stewart, J.W., Tricamo, E., Ocepek-Welikson, K., Harrison, W., Rabkin, J.G., Wager, S.G. & Nunes, E. (1989) Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacology Bulletin, 25, 524-534.
No Pingbacks for this post yet...
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|---|---|---|---|---|---|
| << < | > >> | |||||
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
This blog on Clinical Psychopharmacology is maintained by Dr. Shahul Ameen, M.D., Psychiatrist, St. John's Hospital, Kattappana, Idukki, Kerala, India.
Psychopharmacology Tips is a part of PsyPlexus, a portal for mental health professionals.
This blog is only for educational purpose of psychiatrists and other physicians. The information published in this blog is not intended for use as a substitute for consultation to a licensed health professional. Patients and consumers who visit Psychopharmacology Tips should carefully review the information gathered from the site with a professional healthcare provider.